自家免疫強化療法
参考資料

↑  Rosenberg SA (January 1984). “Adoptive immunotherapy of cancer: accomplishments and prospects”. Cancer Treat Rep 68 (1):  233–55. PMID 6362866.
↑  “Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases”. Int. J. Cancer 105 (4):  512–9. (July 2003). doi:10.1002/ijc.11119. PMID 12712443.
1 2 3  Egawa K (2004). “Immuno-cell therapy of cancer in Japan”. Anticancer Res. 24 (5C):  3321–6. PMID 15515427. http://ar.iiarjournals.org/cgi/pmidlookup?view=long&pmid=15515427.
↑  “Detection of unique neutrophil non-muscle myosin heavy chain-A localization by immunofluorescence analysis in MYH9 disorder presented with macrothrombocytopenia without leukocyte inclusions and deafness”. Eur. J. Haematol. 74 (1):  1–5. (January 2005). doi:10.1111/j.1600-0609.2004.00328.x. PMID 15613099.
1 2  Manjunath, Sadananda Rao; Ramanan, Ganapathi; Dedeepiya, Vidyasagar Devaprasad; Terunuma, Hiroshi; Deng, Xuewen; Baskar, Subramani; Senthilkumar, Rajappa; Thamaraikannan, Paramasivam et al. (2012). “Autologous immune enhancement therapy in recurrent ovarian cancer with metastases; 18 months follow-up- A case report”. Case Reports in Oncology 5 (1):  114–118. doi:10.1159/000337319. PMC 3364094. PMID 22666198. https://www.ncbi.nlm.nih.gov/pubmed?term=Autologous%20immune%20enhancement%20therapy%20in%20recurrent%20ovarian%20cancer%20with%20metastases%3B%2018%20months%20follow-up-%20A%20case%20report.
↑  “Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report-Global Medical Discovery key scientific article”. 16 November 2012時点のオリジナルよりアーカイブ。30 August 2012閲覧。
↑  “Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes”. Clin. Cancer Res. 1 (5):  501–7. (May 1995). PMID 9816009. http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=9816009.
↑  “A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma”. Cancer 80 (1):  42–9. (July 1997). doi:10.1002/(SICI)1097-0142(19970701)80:1<42::AID-CNCR6>3.0.CO;2-H. PMID 9210707.
↑  “Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial”. Lancet 356 (9232):  802–7. (September 2000). doi:10.1016/S0140-6736(00)02654-4. PMID 11022927.
↑  “Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial”. Clin. Cancer Res. 8 (6):  1767–71. (June 2002). PMID 12060615. http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=12060615.
↑  Sharat Damodar; Terunuma H; Sheriff AK; Farzana L; Manjunath S; Senthil KR; Shastikumar G; Abraham S (Nov 2006). Autologous Immune Enhancement Therapy (AIET) for a Case of Acute Myeloid Leukemia (AML) — Our Experience.. 1. pp. 40–41. http://www.pubstemcell.com/monthly/001010700007.htm.
↑  Baskar S, Dedeepiya V D, Terunuma H, Manjunath S R, Senthilkumar R, Sivaraman G, Pandian A, Abraham S. Prolonged survival of a patient with inoperable, locally advanced adenocarcinoma of pancreas after autologous immune enhancement therapy with chemotherapy. Indian J Cancer 2015;52:395-6.
↑  Sumana Premkumar; Vidyasagar Devaprasad Dedeepiya; Hiroshi Terunuma; Rajappa Senthilkumar; Thangavelu Srinivasan; Helen C. Reena; Senthilkumar Preethy; Samuel JK Abraham (2013). “Cell based Autologous Immune Enhancement Therapy (AIET) after radiotherapy in a locally advanced carcinoma of the cervix”. Case Reports in Oncological Medicine 2013:  1–3. doi:10.1155/2013/903094. PMC 3638504. PMID 23653878. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638504/.
↑  Press release on Advanced Ovarian Cancer treated with AIET
↑  Chidambaram R, Terunuma H, Balamurugan M, Dedeepiya VD, Sumana P, Senthilkumar R, Rajmohan M, Karthick R, Preethy S, Abraham SJK. Cell-based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report. Mol Clin Oncol. 2017 Sep;7(3):493-497.
↑  Revathi Raj; M. Deenadayalan; G. Vimal Kumar; Vipin Khandelwal; Karuna Sri; Rajappa Senthilkumar; Samuel J. K. Abraham; Terunuma Hiroshi (2014). “Autologous Immune Enhancement Therapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia”. Journal of Hematology and Blood Transfusion 30 (Suppl 1):  202–204. doi:10.1007/s12288-013-0327-3. PMC 4192214. PMID 25332578. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192214/.
↑  Explore 'Killer Cell' Treatment to Cure rare Cancers
↑  “Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population”. Lancet 356 (9244):  1795–9. (November 2000). doi:10.1016/S0140-6736(00)03231-1. PMID 11117911.
↑  Vidyasagar Devaprasad Dedeepiya; Hiroshi Terunuma; Xuewen Deng; Subramani Baskar; Sadananda Rao Manjunath; Rajappa Senthilkumar; Palanisamy Murugan; Paramasivam Thamaraikannan et al. (February 2012). “A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours”. Oncology Letters 3 (2):  435–440. doi:10.3892/ol.2011.498. PMC 3362377. PMID 22740927. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362377/.